Melina Saban

Dr. Melina Saban

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2019 in European Thyroid Journal
Verified
Journal Article
Closed access
PDF file
MGMaría de Los Ángeles Garayalde Gamboa
María de Los Ángeles Garayalde Gamboa
MSMelina Saban
Melina Saban
MCMarina Ines Curriá
Marina Ines Curriá
Introduction: Orally and daily levothyroxine (LT4) is the treatment of choice for hypothyroidism. In the majority of cases, the lack of effectiveness by this way may be due to poor adherence; however, gastrointestinal malabsorption may explain more cases of thyroxine refractoriness than previously reputed, due to the number of occult forms of these disorders. Case Presentation: A 55-year-old white man with a diagnosis of low risk of recurrence of follicular variant of papillary thyroid carcinoma was treated with total thyroidectomy, 30 mCi iodine 131, and oral LT4. A year before he presented a gastric adenocarcinoma that required a partial gastrectomy. He evolved with multiple episodes of intestinal subocclusion that had to be treated with enterectomy in the first instance, then digestive rest and total parenteral nutrition. In spite of having made increases in oral LT4 dose (3 µg/kg), the patient persisted with a thyroid-stimulating hormone level >100 mIU/L. For this reason, we decided to administer intramuscular LT4. Conclusion: Since there are no guidelines or consensus of intramuscular LT4 use, our experience and how we decided the dose and way of administration are presented in this article to contribute to future cases.

1 May 2005 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
VDVerónica D’aNnunzio
Verónica D’aNnunzio
MDMartin Donato
Martin Donato
MSMelina Saban
Melina Saban
SSSilvia M. Sanguinetti
Silvia M. Sanguinetti
RWRegina L. W. Wikinski
Regina L. W. Wikinski
RGRicardo J. Gelpi
Ricardo J. Gelpi

30 June 2023 in Revista Colombiana de Obstetricia Y Ginecologia
Verified
Journal Article
Open access
PDF file
MSMelina Saban
Melina Saban
GRGabriela Rovira
Gabriela Rovira
MCMarina Inés Curriá
Marina Inés Curriá
Objetivos: describir las características clínicas y sociodemográficas de las gestantes con diagnóstico de diabetes mellitus gestacional (DMG) y evaluar posibles factores asociados al control glucémico fuera de objetivo y requerimiento de insulina.Materiales y métodos: cohorte retrospectiva descriptiva. Se incluyeron mujeres con DMG atendidas en un hospital de referencia entre enero de 2018 y septiembre de 2020; se excluyeron mujeres con parto realizado en otra Institución. Las variables medidas fueron edad, índice de masa corporal al inicio del embarazo, antecedentes familiares de diabetes, edad gestacional al diagnóstico, glucemia basal y glucemia post prueba de tolerancia oral a la glucosa, fructosamina, Hba1c, y uso de insulinoterapia. Se realizó un análisis descriptivo y exploratorio de los factores asociados al mal control glucémico por medio del análisis uni y multivariado.Resultados: el 44 % de las pacientes con DMG presentaron control glucémico fuera de objetivo con medidas higiénico-dietéticas. El análisis exploratorio mostró que podría haber un incremento en el riesgo del mal control glucémico asociado al valor inicial de la glucemia durante la PTOG (OR crudo: 3,57, IC 95 %: 2,1 - 6,1), el IMC > 25 kg/m2 (OR: 1,97, IC 95 %: 1,15 - 3,34) y la mayor edad gestacional al momento del diagnóstico como factor protector del requerimiento de la insulinoterapia (OR: 0,45, IC 95 %: 0,27 - 0,75). Sin embargo, estas asociaciones no se confirmó en el análisis multivariado.Conclusiones: el valor de la glucemia basal mayor a 95 mg/dl, el IMC mayor a 25 kg/m2 podrían estar asociadas al mal control glucémico en las mujeres con DMG. Se necesitan estudios que evalúen estas variables con control de los factores de confusión para determinar los factores que indican el uso de insulina en mujeres gestantes.

1 June 2022 in Endocrinología, Diabetes y Nutrición
Verified
Journal Article
Open access
MSMelina Saban
Melina Saban
MCMelisa Costilla
Melisa Costilla
AKAlicia Juana Klecha
Alicia Juana Klecha
MCMariana Di Cugno
Mariana Di Cugno
MCMarina Inés Curria
Marina Inés Curria
MAMaría Laura Barreiro Arcos
María Laura Barreiro Arcos

7 July 2022 in Endocrine
Verified
Journal Article
Closed access
PDF file
MSMelina Saban
Melina Saban
NTNorma Tolaba
Norma Tolaba
AOAna María Orlandi
Ana María Orlandi
SDSusana Deutsch
Susana Deutsch
FPFabián Pitoia
Fabián Pitoia
OMon behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo
on behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo

23 June 2010 in Gynecological Endocrinology
Verified
Journal Article
Closed access
PDF file
JSJimena Soutelo
Jimena Soutelo
MSMelina Saban
Melina Saban
VQVirginia Quevedo
Virginia Quevedo
EGEugenia Gandur
Eugenia Gandur
APAnalia Paris
Analia Paris
GFGabriel Faraj
Gabriel Faraj
The menopause and the metabolic syndrome (MS) are related with the increase of the risk of cardiovascular diseases. To evaluate the existence of metabolic risk factors and the prevalence of MS in pre- and post-menopausal women. 253 women: 120 pre-menopausal and 133 post-menopausal. Anthropometric, arterial pressure and waist circumference measurements were carried out. Glycaemia, lipids, creatinine, hepatogram, uric acid and thyroid-stimulating hormone were dosed. Statistical higher registries of arterial pressure, levels of glycaemia, total cholesterol, low-density lipoprotein, triglycerides and TG/high-density lipoprotein relation were observed among post-menopausal patients. As regards this group, the MS diagnosis was considerably higher, being the same by all the criteria. We found more prevalence of cardiometabolic and MS risk factors among the group of post-menopausal patients. The responsible mechanisms would respond to the secondary hypoestrogenaemia at the cease of the ovarian function. Because of this fact, menopausal women should be considered a risk group for the development of MS.